This page contains a Flash digital edition of a book.
BIO
TECHNOLOGY
The biggest change in the pharmaceutical markets
currently underway is the continued loss of patent
protection of the industry’s blockbuster drugs as many
of big pharma’s drugs come off-patent, especially in the
5 year period to 2012. This will result in an approximate
50 per cent reduction of all big pharma revenue as these
products become generic with replacement product
development clearly not evident. Into this emerging
market of “generic blockbuster” products competition
will be high to establish replacement generic leaders and
it is within this market that Stirling Products is positioning
its joint ventured High Density Aerosol inhalation devices. intervie
Subject to validation trials, the Company is of the view
that many of these drugs, as they come off-patent, can
be adapted for use through inhalation.
As the Company’s unique technology can provide the
same beneficial effect of drugs with far less product, not
only is this a cost saving but it should prove to also have
less side effect, thereby potentially providing prescription
generic product that has beneficial advantage and
therefore a prescription preference.
Q:
What are the opportunities for trade
with emerging countries such as india,
which has a fast growing biotech industry?
BOONeN: India’s drug industry has moved forward
w
dramatically and it is now acknowledged as one of the
most cost effective manufacturing bases in the world
with a major benefit being the provision of affordable
medications to the Indian population.
For Stirling Products there exists opportunity to form
relationships with the major established pharmaceutical
Peter Boonen interests in India such as Dr Ready, Cipla, Ranbaxy,
Lupin, IPCA Laboratories and Sun Pharma through
products, we are seeking to commercialise these several areas of operation including: joint product
products through major pharma joint ventures. development, partnering the obesity drug candidate,
In summary, we see early significant early sales partnering the High Density Aerosol inhalation technology
and revenue opportunity with our botanical products and securing product supply agreements.
as well as through our recently licensed High Density
Aerosol inhalation platform which we believe to have
major potential as a platform for the possible better
Q:
do you have some facts and figures
about this industry locally or globally?
administration of existing pharmaceutical drugs, BOONeN: The next 10-20 years will see quite some
especially the many blockbusters that are coming dramatic changes and re-positioning in the overall global
off-patent in the 5 year period to 2012. pharmaceutical industry, and particularly positively in India
as it continues its rapid progress. Over the past decade
Q:
What are the biggest developments in
the industry in India has moved from predominantly
your industry right now?
contract manufacture and generics supplier to new
BOONeN: There is an industry focus on the development drug development. Although the large majority of India’s
of natural products – over 60 per cent of all new chemical 15,000 pharmaceutical companies are still small contract
entities in prescription pharmaceuticals developed over manufacturers, the larger pharma enterprises in India are
the past 5 years have been derived from natural or now all heavily involved in drug discovery and research
synthesised natural products. Also over the next 5 years and will prove instrumental in a major shift of market
the global sales of natural health products is expected to share from the current annual market value base of
grow by some 168 per cent to A$36.4 billion per annum. around A$18.7 billion per annum.
With our proven and patented natural botanical products
we are well positioned within this growth market. www.stirlingproducts.net
INVEST IN AUSTRALIA – INDIA 85
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108
Produced with Yudu - www.yudu.com